Market Cap
$343.7M
ARTV
Artiva Biotherapeutics, Inc.
$6.90 ▲ +1.62%
Prev close $6.79Market cap$343.7M
ConsensusStrong Buy
12-mo target$35.80 (+418.8%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)19 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on ARTV right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
42 funds
Inst. Value
$282.4M
Inst. Activity
19 buys / 1 sells
Insider Activity
$6.7M buy / $1.3M sell
Insider Net $
$5.4M
SEC Reports
20
Press Releases
5
Price chart 30d -39.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Sep 15, 2026 SEC Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheu
Four Artiva Biotherapeutics insiders, including the CEO, COO, CTO, and CMO, sold a total of $477K in open-market shares
CLUSTER — Impact 4/10
Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO, sold a total of ~$477K in open-market shares over
CLUSTER — Impact 3/10
Sep 15, 2026 Insider
Aslan Fred was granted 110,000 shares
Chief Executive Officer
Sep 15, 2026 Insider
Sep 14, 2026 SEC Aslan Fred was granted 315,000 shares
Chief Executive Officer
A cluster of insider selling at Artiva Biotherapeutics (ARTV) totaling $477K over the past week, led by CEO Fred Aslan (
CLUSTER — Impact 4/10
Sep 10, 2026 Insider
DANIELS BRIAN was granted 16,250 shares
Director
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — ADD
17,955,642 shares ($174.2M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 2, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Jun 8, 2026 | Needham | REITERATE | Buy | 50% |
| May 12, 2026 | Needham | MAINTAIN | Buy | 50% |
| May 11, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| May 11, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| May 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 4, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Price targets
Where 5 covering analysts think ARTV trades over the next 12 months.
$35.80 +418.8% upside Strong Buy
Current$6.90 Low$23.00 Median$40.00 High$41.00 5 analysts
$23.00$41.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 8 bullish, 3 bearish, 0 mixed, 9 neutral · avg impact 4.6/10.Plus 5 press releases.
NEUTRALCLUSTER4/10
Four Artiva Biotherapeutics insiders, including the CEO, COO, CTO, and CMO, sold a total of $477K in
Sep 15, 2026
NEUTRALCLUSTER3/10
Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO, sold a total of ~$477K in ope
Sep 15, 2026
NEUTRALCLUSTER4/10
A cluster of insider selling at Artiva Biotherapeutics (ARTV) totaling $477K over the past week, led
Sep 14, 2026
NEUTRALCLUSTER3/10
A cluster of insider selling at Artiva Biotherapeutics, totaling $477K, was driven by the CEO, COO,
Sep 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Oct 1, 2026
other
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 20
Sep 8, 2026
other
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Aug 4, 2026
earnings_calendar
ARTV Q2 2026 Earnings Scheduled — 2026-08-04
Jul 17, 2026
other
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to d
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.53 | $-0.56–$-0.47 | 39.3% | +0.0% | — | $0.0B | 5 |
| Next Q | $-0.58 | $-0.65–$-0.54 | 31.4% | +0.0% | — | $0.0B | 5 |
| Current FY | $-2.51 | $-2.63–$-2.30 | 26.8% | +0.0% | 1↑ 0↓ | $0.0B | 5 |
| Next FY | $-2.61 | $-3.31–$-2.25 | -3.9% | +0.0% | 1↑ 0↓ | $0.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.534 | — |
| 7d ago | $-0.534 | — |
| 30d ago | $-0.534 | — |
| 60d ago | $-0.522 | -0.012 |
| 90d ago | $-0.522 | -0.012 |
Institutional ownership
Which big funds own ARTV (from quarterly 13F filings) and who is adding or trimming.
42 institutional holders with $282.4M total value (29,111,672 shares) as of 2026-Q2. Top holders: RA, VIKING, Blackstone. Net buying activity: 19 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 17,955,642 | $174.2M | 61.7% | ADD +82.2% |
| VIKING GLOBAL INVESTORS LP | 2,604,166 | $25.3M | 8.9% | NEW |
| Blackstone Inc. | 2,403,437 | $23.3M | 8.3% | NEW |
| FRANKLIN RESOURCES INC | 1,997,223 | $19.4M | 6.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 981,815 | $9.5M | 3.4% | DOUBLED +372.7% |
| BlackRock, Inc. | 694,726 | $6.7M | 2.4% | DOUBLED +225.6% |
| CITADEL ADVISORS LLC | 609,376 | $5.9M | 2.1% | DOUBLED +3739.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 353,845 | $3.4M | 1.2% | DOUBLED +247.9% |
| Alyeska Investment Group, L.P. | 273,615 | $2.7M | 0.9% | DOUBLED +173.6% |
| WELLINGTON MANAGEMENT GROUP LLP | 194,108 | $1.9M | 0.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | ADD | 9,853,302 | 17,955,642 | +82.2% | $174.2M |
| VIKING GLOBAL INVESTORS LP | NEW | — | 2,604,166 | — | $25.3M |
| Blackstone Inc. | NEW | — | 2,403,437 | — | $23.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | 207,686 | 981,815 | +372.7% | $9.5M |
| BlackRock, Inc. | DOUBLED | 213,388 | 694,726 | +225.6% | $6.7M |
| CITADEL ADVISORS LLC | DOUBLED | 15,870 | 609,376 | +3739.8% | $5.9M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 101,695 | 353,845 | +247.9% | $3.4M |
| Alyeska Investment Group, L.P. | DOUBLED | 100,000 | 273,615 | +173.6% | $2.7M |
| UBS Group AG | DOUBLED | 1,527 | 184,020 | +11951.1% | $1.8M |
| STATE STREET CORP | DOUBLED | 35,824 | 165,764 | +362.7% | $1.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net $5.4M — $6.7M bought, $1.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Aslan Fred | Chief Executive Officer | AWARD | 110,000 | — | — |
| Sep 15, 2026 | Aslan Fred | Chief Executive Officer | AWARD | 315,000 | — | — |
| Sep 10, 2026 | DANIELS BRIAN | Director | AWARD | 16,250 | — | — |
| Sep 10, 2026 | MOORE ALISON | Director | AWARD | 16,250 | — | — |
| Sep 10, 2026 | Stoppel Laura | Director | AWARD | 16,250 | — | — |
| Sep 10, 2026 | Sorg Elaine K. | Director | AWARD | 16,250 | — | — |
| Sep 10, 2026 | Baker Daniel G. | Director | AWARD | 16,250 | — | — |
| Sep 10, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 16,250 | — | — |
| Sep 10, 2026 | Aslan Fred | Chief Executive Officer | AWARD | 45,000 | — | — |
| Sep 10, 2026 | Aslan Fred | Chief Executive Officer | AWARD | 155,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ARTV.
Shares short
2,065,150
Settlement Sep 15, 2026
Change vs prior
+12.5%
Semi-monthly cycle
Days to cover
6.7
At avg daily volume
Of shares outstanding
≈4.2%
Estimate — not % of float
All ARTV filing & press-release reports (28)
- CLUSTER reportSep 15, 2026
- CLUSTER reportSep 15, 2026
- CLUSTER reportSep 14, 2026
- CLUSTER reportSep 12, 2026
- 8-K reportSep 11, 2026
- CLUSTER reportSep 10, 2026
- CLUSTER reportSep 5, 2026
- INST-CLUSTER reportAug 15, 2026
- INSIDER-BUY reportJul 31, 2026
- INSIDER-BUY reportJul 29, 2026
- INSIDER-BUY reportJul 24, 2026
- INSIDER-BUY reportJul 20, 2026
- INSIDER-BUY reportJul 14, 2026
- INSIDER-BUY reportJun 29, 2026
- INSIDER-BUY reportJun 16, 2026
- PRESS-RELEASE reportJun 8, 2026
- CLUSTER reportMay 20, 2026
- PRESS-RELEASE reportMay 19, 2026
- 8-K reportMay 19, 2026
- PRESS-RELEASE reportMay 19, 2026
- 144 reportMay 18, 2026
- 144 reportMay 18, 2026
- 8-K reportMay 8, 2026
- 8-K reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMar 10, 2026
- 8-K, 8-K reportFeb 24, 2026